Journals / Experimed / 2023 / Cilt: 13 Sayı: 2

Evaluation of DNA Microarray in Biomarker Detection in Cell-free DNA from Colorectal Cancer Cell Lines: A Proof-of-Concept Study

Journal
Experimed
Pages
86–92
Publication Date
2023-09-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: We propose that DNA microarray be used to assess the sub-types of certain cancers in a non-invasive manner using cfDNA approaches.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: DNA microarray is a powerful method to identify genomic anomalies including small insertions, duplications and/or deletions.
📊
Key Findings & Data:Results: Our results underlined significant alterations that were deletions and/or duplications in some of the genomic regions in a cell line-specific manner.
💡
Conclusion & Impact:Conclusion: We propose that DNA microarray be used to assess the sub-types of certain cancers in a non-invasive manner using cfDNA approaches.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:cfDNA · carcinogenesis · colorectal cancer

Abstract

Objective: DNA microarray is a powerful method to identify genomic anomalies including small insertions, duplications and/or deletions. This method is widely used in routine genetic screening for explaining the genetic background of certain phenotypes, for example, cancer. Cell-free DNA (cfDNA), which is an approach that may give information about the somatic tissues in peripheral blood, is another popular method used in routine genetic screening to understand the background of particular phenotypes, one of which is cancer. There is limited available research that investigates the involvement of these two approaches to decipher novel cancer biomarkers in the literature. However, detection of cancer biomarkers, especially non-invasive types, has been of great interest to research groups. Materials and Methods: In the present study, we used colorectal cancer as a model tumor to figure out whether we could determine definite biomarkers from cfDNA using DNA microarray methodology. We isolated cfDNA from the cell-free mediums of the cultures of colorectal cancer cell lines in the presence of the control group which was the healthy epithelial colon cell line. Results: Our results underlined significant alterations that were deletions and/or duplications in some of the genomic regions in a cell line-specific manner. Conclusion: We propose that DNA microarray be used to assess the sub-types of certain cancers in a non-invasive manner using cfDNA approaches.

🔖

Cite This Article

KAZAN, H. H., KARAHAN, C. P., ÇELİK, E., ÖZKETEN, A. Ç., BİRGÜCÜ-ÇAĞIL, D., ERGUN, M. A. (2023). Evaluation of DNA Microarray in Biomarker Detection in Cell-free DNA from Colorectal Cancer Cell Lines: A Proof-of-Concept Study. Experimed, Cilt: 13 Sayı: 2, 86–92. https://ajindex.com/articles/962012

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Pineros M, et al. Global cancer observatory: Cancer today. Lyon, France: International Agency for Research on Cancer 2020. Available from: https://gco. iarc.fr/today, accessed 01 February 2023 google scholar 2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin 2021
  2. 71(3): 209-49. google scholar 3. Colorectal cancer facts & figures. American Cancer Society 20202022. Published online, 48. google scholar 4. Petit J, Carroll G, Gould T, Pockney P, Dun M, Scott RJ. Cell-free DNA as a diagnostic blood-based biomarker for colorectal cancer: a systematic review. J Surg Res 2019
  3. google scholar 5. Osborne JM, Wilson C, Moore V, Gregory T, Flight I, Young GP. Sample preference for colorectal cancer screening tests: blood or stool? Open J Prev Med 2012
  4. 02(03): 326-31. google scholar 6. Bronkhorst AJ, Ungerer V, Holdenrieder S. The emerging role of cell-free DNA as a molecular marker for cancer management. Biomol Detect Quantif 2019
  5. 100087. google scholar 7. Alborelli I, Generali D, Jermann P, Cappelletti MR, Ferrero G, Scaggiante B, et al. Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study. Cell Death Dis 2019
  6. 10(7): 534. google scholar 8. Seki Y, Fujiwara Y, Kohno T, Takai E, Sunami K, Goto Y, et al. Picoliter-droplet digital polymerase chain reaction-based analysis of cell-free plasma DNA to assess EGFR mutations in lung adenocarcinoma that confer resistance to tyrosine-kinase inhibitors. Oncologist 2016
  7. 21(2): 156-64. google scholar 9. Palande V, Shay DR, Frenkel-Morgenstern MI. Detection of cell-free DNA in blood plasma samples of cancer patients. JoVE 2020
  8. 9(163): e61449. google scholar 10. Selvaraj S, Natarajan J. Microarray data analysis and mining tools. Bioinformation 2011
  9. 6(3): 95. google scholar 11. Miller MB, Tang YW. Basic concepts of microarrays and potential applications in clinical microbiology. Clin Microbiol Rev 2009
  10. 22(4): 611-33. google scholar 12. Costa P, Novoradovskaya N, Basehore S, Fulmer-Smentek S. Single cell copy number screening using the GenetiSure Pre-Screen kit. Application Note. Agilent Technologies, Inc. 2014. USA, 5991-5325EN. google scholar 13. Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Tra